Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
- Fujimoto’s Safety Procedures TERMS Takes Effect April 1, Celgene’s RevMate June 1
April 10, 2013
- Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
- Trazenta Now Stands at Starting Line Without Concurrent Use Restrictions: NBI President Aono
April 10, 2013
- DSP to Solely Develop Therapeutic Cancer Vaccines, Terminating Joint Development Agreement with Chugai
April 10, 2013
- Teva Japan: Pres. Shimada to Retire, Eli Lilly’s Kikushige to Take Helm
April 9, 2013
- Kowa, Daiichi Sankyo to End Livalo, Olmetec Marketing Partnership in June
April 9, 2013
- Eisai Sets Up Sales Subsidiary in Russia
April 9, 2013
- Ajinomoto Acquires US-Based Althea Technologies to Expand Biotech Operations
April 9, 2013
- Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
- Astellas Collaborates with Ambrx for Discovery and Development of Novel ADCs for Oncology Fields
April 9, 2013
- Novo Nordisk’s FY2012 Sales Dip 0.8% with Insulin Market Subdued by DPP-4 Inhibitors
April 8, 2013
- Abbott Japan Sales Decline 3.2% in 2012 Due to Product Transfer to AbbVie
April 8, 2013
- Survey by JCSOA Finds Big Increase in Use of CMRs to Detail Long-Listed and Non-Priority Products
April 8, 2013
- Teijin Acquires 10% Stake in Kyorin for Strategic Alliance
April 8, 2013
- Bell Medical Solutions Concludes Business Alliance Agreement for CRO Business with inVentiv Health Clinical
April 8, 2013
- Allegra Generic Versions Expected to Be Further Promoted: Pharmacist Survey
April 5, 2013
- Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
- MPD Begins Marketing BindRen in Germany and Austria
April 5, 2013
- Daiichi Sankyo Ends ATK Inhibitor Agreement with ArQule
April 5, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…